Investigational drug · Phase 2
Lipovirtide
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV.
Phase 2Last checked: Nov 20, 2026Latest source record: May 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "Lipovirtide"
First trial start
2023
Nov 2, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lipovirtide", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Lipovirtide" as an intervention, largest first.
Shanxi Kangbao Biological Product Co., Ltd.Industry
NCT06061536 · 64 participants · Start Nov 2, 2023 · Primary completion Nov 29, 2024
Drug: Lipovirtide 10mg; Lipovirtide 40mg and 2 more · For: HIV
Sites: Tianjin, China
Shanxi Kangbao Biological Product Co., Ltd.Industry
NCT04592315 · 46 participants · Start Jan 23, 2021 · Primary completion May 2, 2023
Drug: Lipovirtide Injection · For: HIV Infections
Sites: Beijing, China
Shanxi Kangbao Biological Product Co., Ltd.Industry
NCT05349968 · 24 participants · Start Jun 10, 2022 · Primary completion Jun 7, 2023
Drug: Lipovirtide for injection · For: HIV Infections
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primates.
Zhu Y, Chong H, Liu N, et al. · Antiviral Res 2026
- Pharmacokinetic and safety evaluation of lipopeptide-based HIV fusion inhibitor Lipovirtide in rats.
Zhu Y, Chong H, Liu N, et al. · Antiviral Res 2025
Also in development for HIV
- AlimatravirMK-8527Phase 34 trials
Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, HIV
- Dispensing CodivirPhase 21 trial
Code Pharma · HIV, HIV Infection
- LP-98Phase 21 trial
Shanxi Kangbao Biological Product Co., Ltd. · HIV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.